Our planet is experiencing a psychedelic renaissance as we enter into a new decade. People around the world are transitioning from pharmaceuticals to more natural medicines. As we move into this new form of healthcare are psychologists prepared to use psychedelic therapy?
The improper classification of psychedelics during the 1970’s halted most medical research. Currently private companies and non-profit organizations are leading this research initiative. These research findings are shared with everyone so all humans can have a better quality of life.
The Multidisciplinary Association for Psychedelic Studies found psychedelics can treat alcoholism, end-of-life issues, depression, anxiety, cluster headaches, and post-traumatic stress disorder (PTSD). These complex cognitive situations call for different medical approaches to address underlying issues. It is beneficial for psychologists to have the option to use psychedelics because each patient may need a different approach.
In October of 2018, the US Food and Drug Administration (FDA) reclassified psilocybin mushrooms as a “Breakthrough Therapy” for depression. This was a significant moment because it demonstrated the top governmental health care organization in America saw an overwhelming amount of evidence of psychedelic mushrooms as a medicine.
Many psychologists have learned to avoid and dismiss the possibility of using psychedelics. This view is shifting due to public opinion, decriminalization efforts, and medical research. It is critical for psychologists to accept this medicine because their patients will need guidance before, during, and after psychedelic therapy.